-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The core task of tumor therapy is not to kill most tumor cells, but to control the occurrence and growth of metastatic tumors.
Drug source analysis
The tumorigenesis process is probably like this.
However, the current development and evaluation of tumor drugs mainly depends on whether it can inhibit tumor occurrence and tumor growth in situ in experimental animals, and whether patients can shrink tumors according to RECIST or iRECIST standards.
Obviously, this mainstream model is not to optimize the core task of inhibiting tumor metastasis, but because the current technology makes it easier to take this route from beginning to end.
There are now dozens of drugs with different mechanisms in preclinical studies, mainly based on the over-expression of some genes related to cell migration and other functions in patients with advanced tumors.
The goal of cancer treatment is very clear, which is to prolong life and improve the quality of life.